March 2-5 2020 | London, UK

ReachBio  was a proud sponsor at the World ADC London 2020 conference where the most forward thinking researchers from pharmaceutical, biotech and academic communities disseminated the latest developments regarding antibody-drug conjugates. Its an honor to be in the presence of such a bright community of researchers who openly share their discoveries, progress, and set-backs to further the unified mission of providing eventual cures with antibody drug conjugates.

Our lab is the only contract research organization to partner and exhibit at the largest ADC event that provides assays to assess toxicity and linker stability for organizations developing ADCs. ReachBio brings a unique service to those working in drug discovery and development as our focus is on blood and bone marrow biological assays.

Our Chief Scientific Officer and founder, Dr. Emer Clarke, took the opportunity to hear from the leading researchers and experts who are making advances within the ADC arena and also had the pleasure of fostering new connections with the leaders in the field. It was the perfect setting to facilitate face to face meetings with current clients who are based in Europe and conducting research in this field. Its always a pleasure finally putting names to faces with colleagues who we've only met via teleconferences and emails.

We look forward to continued participation in the most comprehensive ADC conferences where we can align our services with the labs that are focused on the development of their antibody drug conjugate pipelines. We realize that our attendance at this conference was one of the last in the world for the time being while biotech and biological events have been postponed world wide while the unprecedented COVID-19 epidemic crosses the continents. We look forward to a time when we can all safely congregate to continue advances in research.